Oncotype DX® Breast DCIS Score

Patient Comparisons:

DCIS Comparison

Patient Details

55 Year-Old Female Patient

66 Year-Old Female Patient

Charles Leonard, MD Charles Leonard, MD
Post-Menopausal Post-Menopausal
1.6 cm 1.0 cm
ER positive ER positive
Not Provided Not Provided
2 mm 2 mm
2 2
Absent Absent
Not Provided Not Provided
Not Provided Not Provided
Not Provided Not Provided

N/A

N/A

DCIS SCORE™3
DCIS SCORE™57

Clinical Experience

55 Year-Old Female Patient

Prognosis for DCIS Patients

The Breast DCIS Score validation was derived from two studies, E5194 with 327 patients and the Ontario DCIS Cohort Study with 571 patients. The studies consisted of diverse DCIS patient populations treated with breast-conserving surgery alone. The results below reflect a meta-analysis with 773 patients of the two studies incorporating patient age and tumor size with the Breast DCIS Score result to estimate 10-year risk. The meta-analysis excluded patients whose tumors were multifocal and/or had positive margins.1-3

66 Year-Old Female Patient

Prognosis for DCIS Patients

The clinical validation study1 included female patients with DCIS treated with local excision without irradiation, and required clear surgical margins ≥3 mm and a lesion size of ≤2.5 cm. Approximately a third of patients were treated with tamoxifen. The average 10 year rate for ipsilateral breast events for patients who had a DCIS Score of 57 was:


Quantitative hormone receptor analysis

The Oncotype DX test uses RT-PCR to determine the RNA expression of the genes below. These results may differ from ER or PR results reported using other methods or reported by other laboratories.

ER ScoreN/A
PR ScoreN/A

The Oncotype DX test uses RT-PCR to determine the RNA expression of the genes below. These results may differ from ER or PR results reported using other methods or reported by other laboratories.

ER ScoreN/A
PR ScoreN/A

TREATMENT GIVEN: Not Provided
TREATMENT GIVEN: Not Provided

References

1. Solin et al. J Natl Cancer Inst. 2014.
2. Rakovitch et al. Breast Cancer Res Treat. 2015.
3. Rakovitch et al. ASCO. 2017.

References

1. Solin et al. J Natl Cancer Inst. 2014.
2. Rakovitch et al. Breast Cancer Res Treat. 2015.
3. Rakovitch et al. ASCO. 2017.

Submit a Case

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vivamus sodales ultricies elementum.

Online Ordering
& Reports

Login to the Physician Portal to place an order and view patient results.

 

To sign up, please call or email Customer Service at:
+1 (866) ONCOTYPE (866-662-6897)
customerservice@genomichealth.com.

Contact

Contact your Regional Oncogenomic Liaison for more information or case study submissions.

Disclaimer: These case studies are brought to you for educational purposes only and should not be interpreted as an endorsement of Genomic Health or its services by the submitting physician, or any other product or therapy. The information is sometimes related to interpretive diagnostic opinions of the treating physicians, and is not intended to represent the “standard of care.” The case studies reflect real life cases of patients who have used Oncotype DX, however they are individual results and results do vary. The examples are not necessarily representative of all of those who will use our clinical tests. Genomic Health does not endorse any of the contributors featured on this site.